RNTX
Rein Therapeutics, Inc.
Latest Form 4:Purchase$4KbyVON RICKENBACH JOSEF H (Director) · filed May 29, 2026
Rein Therapeutics, Inc. (RNTX) has 4 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: May 29, 2026.
The most active filer is Director VON RICKENBACH JOSEF H with 4 filings.
- Industry:Medical - Pharmaceuticals
- CEO:James Brian Windsor
- Employees:10
- HQ:Austin, TX, US
- IPO:2017-06-29
Insider Buying
$626K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$68.4M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 3,420 | $4K | May 29 | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 15,950 | $17K | May 29 | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 23,190 | $24K | May 29 | SEC ↗ |
VON RICKENBACH JOSEF HFirst filing | Director | Purchase | 4,500 | $5K | May 29 | SEC ↗ |
WINDSOR JAMES BRIANFirst filing | See Remarks | Purchase | 25,000 | $25K | May 13 | SEC ↗ |
| 10% Owner | Purchase | 104,183 | $128K | Nov 18 | SEC ↗ | |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 30,176 | $42K | Oct 28 | SEC ↗ |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 97,482 | $134K | Oct 28 | SEC ↗ |
Voss Capital, LPFirst filing | 10% Owner | Purchase | 178,392 | $248K | Oct 28 | SEC ↗ |
Related companies
Rein Therapeutics, Inc. is in the Healthcare sector.